Alicia Ciccone

Researchers sought to determine whether treatment with ocrelizumab improved measures of cognitive function better than interferon beta 1-a.

Initial trials of teriflunomide have demonstrated low lymphocyte counts in patients with relapsing forms of MS.

Zika virus spread for months before being detected by public health officials, according to genetic analysis. Plus, can fidget spinners really quell symptoms of ADHD and autism?

In patients with MS, hand function often correlates with measures of quality of life.

The prevalence of osteoporosis was greater in patients with MS than in matched controls.

Cognitive fatigue and anxiety are common symptoms reported by patients with multiple sclerosis.

Boys with onset of MS during puberty experienced an increased rate of relapse compared with boys with MS onset before or after puberty.

Patients with trigeminal neuralgia face a significant burden of illness.

What US hospitals can learn from the ransomware attack on the UK health care system, plus the latest hurdle for Sarepta’s DMD drugs.

A new treatment for ALS gets a green light from the FDA as the NIH prepares to take a deep dive into chronic fatigue syndrome.

Men who received testosterone replacement therapy had lower odds of cardiovascular events.

A third of the population has experienced “mini” stroke, but most don’t know how to handle it. Plus, catch up on the latest drug price controversy for rare-disease drugs.

Did you miss out on AAN? Catch up on the latest science with Neurology Advisor’s live coverage, plus learn about the latest FDA approval.

Treatment with the monoclonal antibody erenumab reduced the number of monthly migraine days experienced in patients with episodic migraine.

Results from 2 phase 3 clinical trials demonstrated efficacy of adjunctive cannabidiol for the treatment of drop seizures in Lennox-Gastaut syndrome.

Resumption of oral anticoagulants after intracerebral hemorrhage was found to improve outcomes at 1 year.

In older patients with relapsing multiple sclerosis, patient-reported fatigue and problems with lower extremities may signal conversion to secondary progressive disease.

Previous research had suggested that the benefits of IV tPA are diminished in patients weighing more than 100 kg.

A report ties over 4000 children with birth defects to a popular epilepsy drug, while the FDA issues a stern warning about the use of codeine and tramadol in children.

This year’s annual meeting of the American Academy of Neurology takes place in Boston, MA from April 22-28, 2017.

The latest studies suggest that silencing the SCA2 gene may help reduce symptoms of ALS and deep brain stimulation may quell tics associated with Tourette’s syndrome.

Valbenazine is the first drug approved for the treatment of tardive dyskinesia, an adverse effect associated with the use of some antipsychotic medications.

Teva’s Huntington’s chorea drug names a competitive price as other drug makers pursue phase 3 studies in glioblastoma and depression despite disappointing data.

Deutetrabenazine is only the second drug approved for patients with Huntington’s disease.

Patients with subclinical hypothyroidism scored worse on tests of processing speed than patients with normal thyroid function.

Pricing criticism strikes Roche’s Ocrevus as the nominee for FDA commissioner comes under fire for potential conflicts of interest.

The biannual infusion is approved for the treatment of adults with relapsing and progressive forms of multiple sclerosis.

Admission hyperglycemia was associated with poststroke infection, as well as 3-month functional outcome and mortality.

No significant between-group differences were observed for change in leg pain intensity and disability.

The CDC says we should be paying more attention to fall-related concussion prevention in the elderly while one of the NFL’s own heads to Harvard for a neurosurgery residency.